Loading stock data…
$21.21+2.09 (+10.93%)
Scribe Therapeutics Inc.
| Metric (USD) | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Total Revenue | $1.92M↓ | $2.23M↓ | $4.90M↓ | $17.13M |
| Gross Profit | — | — | — | — |
| Operating Income | -$9.39M↑ | -$12.43M↓ | -$11.63M↓ | -$5.56M |
| Net Income | -$6.48M↑ | -$17.35M↓ | -$9.90M↓ | -$3.42M |
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in th...